Abstract

Provided is use of a new immune checkpoint PIEZO1 pathway in tumor T-cell therapy. A PIEZO1 inhibitor can be used for treating cancers, improving the killing ability of T cells, and improving the therapeutic effect of an immune checkpoint inhibitor.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

A use of uridine diphosphate glucose (UDPG) in treatment of abnormal liver glucolipid metabolism. Specifically, a use of UDPG or a pharmaceutical composition comprising same in the preparation of a drug for preventing and/or treating abnormal liver glucolipid metabolism, wherein the abnormal liver glucolipid metabolism is preferably nonalcoholic fatty liver disease, dyslipidemia and related cardiovascular diseases. Treatment using UDPG can reduce lipid synthesis and lipid synthesis related gene expression in the liver.

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/06 - Antihyperlipidemics
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention relates to a use of indanyl levulinate in the prevention and/or treatment of muscle atrophy-related diseases. Specifically, the present invention relates to a use of an indanyl levulinate compound as represented by formula (I) or a pharmaceutical composition comprising same in the prevention and/or treatment of muscle atrophy-related diseases including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, and neurogenic muscle atrophy. The compound of the present invention has significant effects in the prevention and/or treatment of muscle atrophy-related diseases by promoting asymmetric division of skeletal muscle stem cells.

IPC Classes  ?

• A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a construct for the real-time tracing of spatial genome conformation and transcription products in living cells and the use thereof. Specifically, provided is a construct, which is a multifunctional DNA and RNA imaging tool (abbreviated to DRIT). The construct is used in the design/preparation method of transgenic animals, and is used for real-time in-situ tracing of spatial genome conformation and labeling and tracing of nascent transcription products in living cells.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• C12N 15/55 - Hydrolases (3)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention relates to a human papillomavirus type 18 chimeric protein and the use thereof. Specifically, the present invention relates to a papillomavirus chimeric protein, which comprises or consists of an HPV type 18 L1 protein or a mutant of the HPV type 18 L1 protein, and a polypeptide from a HPV type 59 L2 protein inserted into the surface region of the HPV type 18 L1 protein or the mutant of the HPV type 18 L1 protein, wherein the amino acid sequence of the HPV type 18 L1 protein is as shown in SEQ ID No. 1, and the amino acid sequence of the HPV type 59 L2 protein is as shown in SEQ ID No. 2.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/20 - Antivirals for DNA viruses
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to the use of a lithium-containing compound in the treatment of tumors. In particular, the present invention relates to the use of a lithium-containing compound in the preparation of a drug for treating tumors.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Disclosed is the use of cellular microparticles in the treatment of respiratory viral pneumonia. Tumor-cell-derived microparticles (MPs), which comprise a cellular vesicle released by an apoptotic tumor cell. The cellular vesicle expresses a spike protein binding receptor on the surface thereof. The MPs have high biosafety. In addition, it is found that the receptor on the surface of the microparticle has an ability to adsorb a virus, and macrophages can efficiently ingest the MPs, which can be used for treating viral pneumonia.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 5/09 - Tumour cells

Abstract

Disclosed are a human papillomavirus type 16 DNA vaccine and use thereof, which relate to the technical field of biology. An antigen gene of the present invention is an optimized human papillomavirus type 16 E6 protein and E7 protein fusion gene, and a human heat shock protein 70 gene is further fused downstream thereof. A vaccine plasmid further comprises a replication origin and a CpG motif-based immunostimulatory sequence. The human papillomavirus type 16 DNA vaccine disclosed can induce an HPV16 E6 and E7 antigen specific cellular immune response by means of intramuscular injection electroporation immunization. The DNA vaccine can be used for preventing and treating HPV16 infection, and treating infection-related precancerous lesions and malignant tumors.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61P 31/20 - Antivirals for DNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a spermine derivative and therapeutic use thereof for diseases. Specifically, the present invention relates to a spermine derivative represented by formula I, a pharmaceutical composition comprising same, and use thereof in treating inflammatory diseases and autoimmune diseases.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines

Abstract

The present application relates to use of spermine in preventing and treating inflammatory diseases. Specifically, spermine, a pharmaceutically acceptable salt of spermine, a reagent targeting a spermine decomposition enzyme, a reagent targeting spermine synthase, and a reagent targeting ornithine decarboxylase are provided for a subject and can be used for preventing or treating inflammatory diseases.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators

Abstract

The present invention relates to a novel compound CX-1 and therapeutic use thereof in inflammatory diseases and tumors. Specifically, the present invention relates to a compound CX-1 represented by formula I, a pharmaceutical composition comprising same, and use thereof in treating inflammatory diseases, autoimmune diseases, or tumors.

IPC Classes  ?

• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is use of a reagent for detecting an eosinophil, an eosinophil and a cytoplasm content thereof, and a lipid metabolite hydroxy docosahexaenoic acid, which belongs to the technical field of medical treatment and medicines. Provided is use of the reagent for detecting an eosinophil in preparing a product for diagnosing pulmonary hypertension and/or determining the prognosis risk of pulmonary hypertension. By means of detecting the proportion of EOS in the peripheral blood, the diagnosis of pulmonary hypertension and the determination of the prognosis risk of pulmonary hypertension can be realized.

IPC Classes  ?

• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid

Abstract

Provided are a lipid compound for nucleic acid delivery, and related use and a medicament comprising same. Particularly, provided are use of a lipid compound comprising one or more compounds represented by the following formula (I) in preparing a product for nucleic acid delivery, a pharmaceutical composition comprising the lipid compound and a nucleic acid molecule, and use of the pharmaceutical composition.

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to use of a glycerophospholipid compound in the prevention and treatment of hyperlipidemia, atherosclerosis, a non-alcoholic fatty liver disease, and obesity. Specifically, the present invention relates to use of a glycerophospholipid compound having a structure represented by formula (I) in the preparation of a medicament for preventing and/or treating hyperlipidemia, atherosclerosis, a non-alcoholic fatty liver disease, or obesity. The compounds described in the present invention can have the effects of reducing fat, alleviating atherosclerosis, alleviating non-alcoholic fatty liver disease, and combating obesity by inducing a reduction in the volume of a white adipose tissue or the browning of a white adipose tissue.

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 3/06 - Antihyperlipidemics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Disclosed are a class of lycorine derivatives represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The lycorine derivatives have significant antiviral activity and can be used for treating viral diseases.

IPC Classes  ?

• C07D 491/16 - Peri-condensed systems
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a human papillomavirus type 31 chimeric protein and a use thereof. Specifically, the present invention relates to a human papillomavirus chimeric protein, containing or being composed of an HPV31L1 protein or HPV31L1 protein mutant, and a polypeptide derived from an HPV73L2 protein and inserted into the HPV31L1 protein or HPV31L1 protein mutant, wherein the HPV31L1 protein is as shown in SEQ ID No. 1, and the HPV73L2 protein is as shown in SEQ ID No. 2.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

Provided are an HPV chimeric protein and a use thereof. The HPV chimeric protein of the present invention comprises an HPV58 L1 protein or a mutant thereof and a polypeptide derived from a HPV16 L2 protein and inserted into a surface region of the HPV58 L1 protein or the mutant thereof, or consists of the polypeptide, wherein an amino acid sequence of the HPV58 L1 protein is as shown in SEQ ID No. 1 and an amino acid sequence of the HPV16 L2 protein is as shown in SEQ ID No. 2.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present disclosure provides use of a reagent for detecting retinol metabolites in preparation of a tool for diagnosing and/or treating pneumoconiosis, and relates to the technical field of biomedicine. The present disclosure verifies that retinol metabolism disturbance and all-trans retinoic acid (ATRA) deficiency are closely related to the pathogenesis of pneumoconiosis. Therefore, the present disclosure sets forth use of retinol and ATRA as biomarkers for screening the pneumoconiosis and use thereof in preparation of products related to the diagnosis of the pneumoconiosis; meanwhile, intervention of the pneumoconiosis with the ATRA can effectively delay the progression of the pneumoconiosis. Therefore, the present disclosure first sets forth use of the ATRA as a medicament for treating the pneumoconiosis.

IPC Classes  ?

• A61K 31/203 - Retinoic acids
• A61P 11/00 - Drugs for disorders of the respiratory system
• G01N 30/72 - Mass spectrometers

Abstract

The present application relates to a modified human papillomavirus (HPV) type 52 L1 protein and a use thereof. Specifically, the present application relates to a HPV type 52 L1 protein, a nucleotide encoded thereby, a carrier comprising the nucleotide, a cell comprising the carrier, a pentamer or virus-like particle consisting of the HPV-52 L1 protein, a vaccine comprising the pentamer or virus-like particle and a vaccine adjuvant, and a use thereof in the prevention of HPV infections and HPV infection-related diseases.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/12 - Viral antigens

Abstract

The present application relates to a C-terminus modified human papillomavirus type 6 L1 protein and use thereof. Specifically, the present application relates to a C-terminus modified human papillomavirus (HPV) type 6 L1 protein, an encoded nucleotide thereof, a vector comprising the nucleotide, a cell comprising the vector, a pentamer or virus-like particle composed of the HPV6 L1 protein, a vaccine containing the pentamer or virus-like particle and a vaccine adjuvant, and the use thereof in prevention of HPV infection and HPV infection-related diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants

Abstract

The present application relates to a C-terminus modified human papillomavirus type 11 L1 protein and the use thereof. Specifically, the present application relates to a C-terminus modified human papillomavirus (HPV) type 11 L1 protein, a nucleotide encoded thereby, a vector containing the nucleotide, a cell containing the vector, a pentamer or virus-like particle composed of the HPV11 L1 protein, and a vaccine containing the pentamer or virus-like particle and a vaccine adjuvant, and the use thereof in the prevention of HPV infection and HPV infection-related diseases.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present disclosure provides use of malic enzyme 2 (ME2) in preparation of a diagnostic reagent or a medicament for silicosis or pulmonary fibrosis-related diseases, and belongs to the technical fields of medical treatment and medicine. Research results of the present disclosure show that ME2 knockout significantly alleviates inflammatory response and fibrotic lesions in mice with silicosis. Based on the above research results, the present disclosure provides use of ME2 in treatment of pulmonary inflammatory responses and pulmonary fibrotic lesions of silicosis or pulmonary fibrosis-related diseases. Expression of ME2 is inhibited to alleviate the inflammatory response and fibrotic lesions of the silicosis, providing support for exploring a targeted drug for treating pulmonary inflammatory responses and pulmonary fibrosis of silicosis or pulmonary fibrosis-related diseases.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase

Abstract

The present disclosure provides use of an FcγRIII inhibitor for treating pulmonary fibrosis, and belongs to the technical field of biomedicine. Results indicate that FcγRIII mediates macrophage phagocytosis of silica particles, FcγRIII knockout can effectively relieve pulmonary inflammatory response and fibrotic lesions in mice with silicosis, and further intratracheal administration of an anti-FcγRIII antibody significantly delays disease progression of mice at fibrosis phase. Therefore, the present disclosure first sets forth that the FcγRIII inhibitors can be used for treating pulmonary fibrosis, which is of importance to the screening of new drugs and provides a new idea for treatment of pulmonary fibrosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present disclosure is directed to methods of administering tetrandrine in combination with all-trans retinoic acid (ATRA) for treating pneumoconiosis. Administration of ATRA in combination with tetrandrine can effectively alleviate the progression of silicosis: impaired cardiopulmonary functions of mice with silicosis are improved significantly, including inspiratory capacity, quasi-static compliance, and right ventricular pressure; concentrations of inflammatory factors IL-1β and IL-6 in bronchoalveolar lavage fluids of mice with silicosis decrease, and the number of inflammatory cells is reduced; levels of fibrosis factors FN-1 and Col-I decrease, fibrous foci are reduced, and pathological degree is alleviated. Moreover, combination therapy with ATRA in combination with tetrandrine shows a superiority of combined administration in terms of cardiopulmonary function, inflammation and fibrosis, and exhibits a better effect than administration of tetrandrine alone.

IPC Classes  ?

• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/203 - Retinoic acids
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present application relates to a molecular marker for red blood cell denucleation and a use thereof. According to a method for identifying or sorting red blood cells being denucleated, by detecting markers such as CD44, CD235a or Ter119, and CD45, red blood cells being denucleated are specifically identified.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention discloses a polypeptide that specifically binding to CD123 protein, a polypeptide complex and a co-delivery system, and preparation methods and use thereof. The general formula of amino acid arrangement in the polypeptide is X1-DYDTR-X2-QGTD-X3-G-X4-DFRRISD-X5; it can bind to CD123-positive cells and inhibit the progression of leukemia; the polypeptide complex can increase the binding quantity of the polypeptide to CD123-positive cells, and drug can inhibit the progression of leukemia alone and prolong the survival of leukemia mice; the co-delivery system can load chemotherapy drugs for tumor treatment and reduce the toxicity of chemotherapy drugs to normal cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

Provided are small RNA and a use thereof in the treatment of hyperlipidemia. Specifically, provided are an isolated nucleic acid molecule as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 75, a vector comprising same, a host cell, a pharmaceutical composition, and a use of the nucleic acid molecule in the preparation of a drug for treating hyperlipidemia.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 3/06 - Antihyperlipidemics

Abstract

Provided is a small RNA drug for inhibiting the activity of cancer cells. Specifically, provided are an isolated nucleic acid molecule as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 133, or an isolated nucleic acid molecule as shown in a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98, and 99% sequence identity therewith, a vector, a host cell, and a pharmaceutical composition comprising same, and a use thereof in treatment of cancers.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided is use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia. Specifically, provided is a nitrogen-containing bisphosphonate in combination with a glucocorticoid for use in treating or ameliorating coronavirus infections, the nitrogen-containing bisphosphonate is selected from the group consisting of pamidronate, alendronate, risedronate, ibandronate, zoledronate, minodronate and incadronate. The glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone, fluticasone propionate, beclomethasone dipropionate, budesonide and mometasone furoate.

IPC Classes  ?

• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Disclosed are a compound as shown in formula I capable of inhibiting inflammasome nucleotide oligomerization domain-like receptor protein 3 (NLRP3) and inhibiting the secretion of interleukin-1β (IL-1β), and a preparation method therefor. ELISA experiments show that this type of compound can significantly inhibit the activity of NLRP3 and reduce the expression of the inflammatory factor IL-1β downstream of NLRP3. The compound of formula I is expected to become a new anti-inflammatory drug and a drug for treating autoimmune diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds can promote the absorption, particularly oral absorption, of nucleic acids, and promote entry of nucleic acids into target sites in a subject in need thereof.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds can promote the absorption, particularly oral absorption, of nucleic acids, and promote entry of nucleic acids into target sites in a subject in need thereof.

IPC Classes  ?

• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders

Abstract

A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds provided above can promote the absorption, particularly oral absorption, of nucleic acids, and promote the entry of nucleic acids into target sites in a subject in need thereof.

IPC Classes  ?

• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds provided above can promote the absorption, particularly oral absorption, of nucleic acids, and promote the entry of nucleic acids into target sites in a subject in need thereof.

IPC Classes  ?

• C07C 219/00 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
• C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

An antiviral use and a broad-spectrum anti-inflammatory effect of a lipid small molecule as a 3C-like protease targeting agent. Specifically, by screening 3C-like protease of a virus (for example, SARS-CoV-2) by means of a traditional Chinese medicine lipid molecule library, a drug lead compound is obtained, and a virus challenge experiment is used to prove that phosphatidylcholine and diglycerides have antiviral and anti-inflammatory effects.

IPC Classes  ?

• A61K 31/664 - Amides of phosphorus acids
• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Use of glycerophospholipid compounds in the preparation of a drug for the treatment of tumor, particularly malignant tumor. The glycerophospholipid compounds can induce ferroptosis of tumor cells, and has the anti-tumor effect.

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is the use of cellular microparticles in the treatment of respiratory viral pneumonia. Tumor-cell-derived microparticles (MPs), which comprise a cellular vesicle released by an apoptotic tumor cell. The cellular vesicle expresses a spike protein binding receptor on the surface thereof. The MPs have high biosafety. In addition, it is found that the receptor on the surface of the microparticle has an ability to adsorb a virus, and macrophages can efficiently ingest the MPs, which can be used for treating viral pneumonia.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The present application relates to use of a reagent targeting a GSDME pathway in preparation of a drug for treating pancreatic cancer. By targeting the member acting on the GSDME pathway, such as GSDME, MUC 1, or MUC 13, it can break the resistance of tumor cells against digestive enzymes and destroy the in-situ growth of pancreatic tumors.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Disclosed in the present invention are a polypeptide and a polypeptide composition specifically binding to a SARS-CoV-2 spike protein, and preparation methods therefor and the uses thereof. By means of binding to an S1 protein, the polypeptide and the polypeptide composition can block the binding of SARS-CoV-2 virus to a key target protein angiotensin-converting enzyme 2 (ACE2) protein on the surface of a host cell thereof, thereby providing a feasible targeting drug for the treatment of novel coronavirus pneumonia.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 31/14 - Antivirals for RNA viruses
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Disclosed are a heterogeneous stem cell population, a preparation method therefor, and the use thereof. Specifically, disclosed is a heterogeneous stem cell population, characterized in that stem cells in the heterogeneous stem cell population express stemness genes MYC, KLF4, GMNN, SOX2 and NANOG, and in the heterogeneous stem cell population, the ratio of stem cells expressing CD146 is 1%-50%.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells

Abstract

Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present disclosure can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/65 - Tetracyclines
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 38/13 - Cyclosporins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/21 - Interferons
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 36/37 - Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
• A61K 49/00 - Preparations for testing in vivo
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a human papillomavirus type 31 chimeric protein and a use thereof. Specifically, the present invention relates to a human papillomavirus chimeric protein, containing or being composed of an HPV31 L1 protein or HPV31 L1 protein mutant, and a polypeptide derived from an HPV73 L2 protein and inserted into the HPV31 L1 protein or HPV31 L1 protein mutant, wherein the HPV31 L1 protein is as shown in SEQ ID No. 1, and the HPV73 L2 protein is as shown in SEQ ID No. 2.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61P 35/00 - Antineoplastic agents
• A61K 39/12 - Viral antigens

Abstract

Provided are an HPV chimeric protein and a use thereof. The HPV chimeric protein of the present invention comprises an HPV58 L1 protein or a mutant thereof and a polypeptide derived from a HPV16 L2 protein and inserted into a surface region of the HPV58 L1 protein or the mutant thereof, or consists of the polypeptide, wherein an amino acid sequence of the HPV58 L1 protein is as shown in SEQ ID No. 1 and an amino acid sequence of the HPV16 L2 protein is as shown in SEQ ID No. 2.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present invention relates to a human papillomavirus type 18 chimeric protein and the use thereof. Specifically, the present invention relates to a papillomavirus chimeric protein, which comprises or consists of an HPV type 18 L1 protein or a mutant of the HPV type 18 L1 protein, and a polypeptide from a HPV type 59 L2 protein inserted into the surface region of the HPV type 18 L1 protein or the mutant of the HPV type 18 L1 protein, wherein the amino acid sequence of the HPV type 18 L1 protein is as shown in SEQ ID NO. 1, and the amino acid sequence of the HPV type 59 L2 protein is as shown in SEQ ID NO. 2.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61P 35/00 - Antineoplastic agents
• A61K 39/12 - Viral antigens

Abstract

Provided are a cell-penetrating peptide based on influenza virus M2 protein and a method for preparing and transforming same. Further provided are a conjugate containing the cell-penetrating peptide, a fusion protein and a composition, wherein the cell-penetrating peptide can be used for penetrating cells, introducing a molecule into cells and treating diseases.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61P 35/00 - Antineoplastic agents
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present application relates to a modified human papillomavirus (HPV) type 52 L1 protein and a use thereof. Specifically, the present application relates to a HPV type 52 L1 protein, a nucleotide encoded thereby, a carrier comprising the nucleotide, a cell comprising the carrier, a pentamer or virus-like particle consisting of the HPV-52 L1 protein, a vaccine comprising the pentamer or virus-like particle and a vaccine adjuvant, and a use thereof in the prevention of HPV infections and HPV infection-related diseases.

IPC Classes  ?

• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
• C12N 15/866 - Baculoviral vectors
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present application relates to a C-terminus modified human papillomavirus type 6 L1 protein and use thereof. Specifically, the present application relates to a C-terminus modified human papillomavirus (HPV) type 6 L1 protein, an encoded nucleotide thereof, a vector comprising the nucleotide, a cell comprising the vector, a pentamer or virus-like particle composed of the HPV6 L1 protein, a vaccine containing the pentamer or virus-like particle and a vaccine adjuvant, and the use thereof in prevention of HPV infection and HPV infection-related diseases.

IPC Classes  ?

• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present application relates to a C-terminally modified human papillomavirus type 11 L1 protein and the use thereof. Specifically, the present application relates to a C-terminally modified human papillomavirus (HPV) type 11 L1 protein, a nucleotide encoded thereby, a vector containing the nucleotide, a cell containing the vector, a pentamer or virus-like particle composed of the HPV11L1 protein, and a vaccine containing the pentamer or virus-like particle and a vaccine adjuvant, and the use thereof in the prevention of HPV infection and HPV infection-related diseases.

IPC Classes  ?

• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
• C12N 15/866 - Baculoviral vectors
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The use of a lipid compound in the prevention or treatment of diabetes. The lipid compound provided is a PPAR-γ agonist, which, via oral absorption, can relieve glucose tolerance, reduce body weight, and does not cause myocardial damage. The lipid compound provided may be extracted from traditional Chinese medicines and may also be obtained by means of synthetic methods. Compared with the conventional drug rosiglitazone, the lipid compound provided can ameliorate the side effect of myocardial damage caused by said conventional drug.

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention discloses a dual-drug co-delivery system, a preparation method therefor and use thereof, the dual-drug co-delivery system being prepared from raw materials comprising a block copolymer, Homoharringtonine and Doxorubicin hydrochloride. The dual-drug co-delivery system provided by the present invention has a stronger killing effect on various hematologic tumors and solid tumor cells, can provide a feasible drug delivery system for inhibiting tumor growth and leukemia treatment, and has broad prospects.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 9/08 - Solutions
• A61K 9/107 - Emulsions
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

123455. The development of leukemia can be inhibited by combining with CD123 positive cells. The polypeptide complex can increase the number of polypeptides bound to the CD123 positive cells. A single drug can inhibit the development of leukemia and prolong the lifetime of the leukemia mice. The co-delivery system can load chemotherapy drugs for tumor treatment, thereby reducing the toxicity of the chemotherapeutic drugs to normal cells.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 9/107 - Emulsions
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

This application provides the use of small molecule inhibitors in the treatment of respiratory viral pneumonia. In particular, this application relates to new use of AhR inhibitors in the treatment or improvement of respiratory virus infection. The inhibitors for treatment of viral infection provided in the present application can effectively inhibit the pathological mucus produced by the virus-induced lung tissue, and AhR inhibitors are expected to become potential agent for the treatment of lung diseases caused by respiratory viral infection.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Provided is a method for constructing a mouse tumor model by using a single tumor cell. Specifically, the method comprises a step of transplanting a fibrin glue that comprises a single tumor cell into a mouse; and preferably, the method comprises a step of transplanting a fibrin glue that comprises a single tumor cell to under the skin of a mouse.

IPC Classes  ?

• C12N 5/095 - Stem cellsProgenitor cells
• A61K 49/00 - Preparations for testing in vivo

Abstract

Disclosed is the use of a pyroptosis pathway in cell therapy, the use comprising: the use of a Gasdermin E-mediated pyroptosis pathway in the prediction and/or treatment of cytokine release syndrome, the use of a reagent for specifically detecting the activity or level of GSDME protein or gene in the preparation of a kit for predicting the risk of cytokine release syndrome occurring in a subject, and the use of a reagent for blocking and/or inhibiting the activity or level of GSDME protein or gene in the preparation of a drug for inhibiting and/or reducing the occurrence of cytokine release syndrome in a subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups

Abstract

Disclosed is a use of a transport protein inhibitor in the preparation of a drug for preventing or treating diseases accompanied with increased PD-1 expression. The drug is capable of effectively reducing the expression of PD-1 in specific CD8+ T cells and enhancing the killing effect of specific CD8+ T cells on tumor cells.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• A61K 9/14 - Particulate form, e.g. powders
• A61K 33/36 - ArsenicCompounds thereof
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 7/06 - Antianaemics
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Disclosed are the use of one or more lipid compounds in the delivery of nucleic acids, and a lipid-nucleic acid mixture, a pharmaceutical composition or a kit comprising the lipid compound and nucleic acids. The lipid compounds provided in the present invention can promote the absorption of nucleic acids, particularly via oral absorption, and can promote the entry of nucleic acids at target sites in a subject in need thereof.

IPC Classes  ?

• C07C 219/00 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
• C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
• C07C 233/00 - Carboxylic acid amides
• C07F 9/09 - Esters of phosphoric acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present invention can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61K 49/00 - Preparations for testing in vivo
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Disclosed are a heterogeneous stem cell population, a preparation method therefor, and the use thereof. Specifically, disclosed is a heterogeneous stem cell population, characterized in that stem cells in the heterogeneous stem cell population express stemness genes MYC, KLF4, GMNN, SOX2, and NANOG, and in the heterogeneous stem cell population, the ratio of stem cells expressing CD146 is 1%-50%.

IPC Classes  ?

• C12N 5/074 - Adult stem cells

Abstract

Disclosed are a heterogeneous stem cell population, a preparation method therefor, and the use thereof. Specifically, disclosed is a heterogeneous stem cell population, characterized in that stem cells in the heterogeneous stem cell population express stemness genes MYC, KLF4, GMNN, SOX2, and NANOG, and in the heterogeneous stem cell population, the ratio of stem cells expressing CD146 is 1%-50%.

IPC Classes  ?

• C12N 5/074 - Adult stem cells

Abstract

A dual-drug co-delivery system, a preparation method therefor and an application thereof, the dual-drug co-delivery system being prepared from raw materials comprising a block copolymer, homoharringtonine and doxorubicin hydrochloride; the co-delivery system has a stronger killing effect on various blood tumors and solid tumor cells, can provide a feasible drug delivery system for inhibiting tumor growth and leukemia treatment, and has broad prospects.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

A method for detecting pores on cell membrane using an atomic force microscope, comprising the steps of: providing cells; fixing the cells in place; and observing the cells by means of an atomic force microscope. The pores are present in the cell membrane or pass through the cell membrane. By means of the present method, the presence of pores in the cell membrane can be accurately observed, and the size and depth of the pores can be accurately determined.

IPC Classes  ?

• G01Q 60/34 - Tapping mode

Abstract

Provided is a small RNA, a composition comprising the small RNA, a method for using same and use of same. The small RNA or composition can inhibit the ability of any one or more of pathways or genes listed in Table 3, or decrease or down regulate the expression level of IL-1 beta, IL-6, and/or TNF-alpha in vivo or in vitro, or treat or prevent IL-1 beta, IL-6, and/or TNF-alpha related diseases and/or increase cell viability in a subject.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided are a cell-penetrating peptide based on influenza virus M2 protein and a method for preparing and transforming same. Further provided are a conjugate containing the cell-penetrating peptide, a fusion protein and a composition, wherein the cell-penetrating peptide can be used for penetrating cells, introducing a molecule into cells and treating diseases.

IPC Classes  ?

• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• C07K 19/00 - Hybrid peptides
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 35/00 - Antineoplastic agents
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Provided are a cell-penetrating peptide based on influenza virus M2 protein and a method for preparing and transforming same. Further provided are a conjugate containing the cell-penetrating peptide, a fusion protein and a composition, wherein the cell-penetrating peptide can be used for penetrating cells, introducing a molecule into cells and treating diseases.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• C07K 19/00 - Hybrid peptides
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor

Abstract

The invention discloses a conjugate constructed by conjugating a HSP90 inhibitory peptide to cytotoxic agent via linker and use thereof in the preparing medicine for preventing and/or treating tumor. The mentioned conjugates possess triple anti-tumor effects including targeting delivery, chemotherapy and apoptosis-promotion, which can enhance the anti-tumor efficacy, reduce the dosage, and decrease the toxicity induced by accumulation of chemotherapeutics.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 38/08 - Peptides having 5 to 11 amino acids

Abstract

Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61K 9/14 - Particulate form, e.g. powders
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Provided are an artificially synthesized sphingosine lipoid monomer and the use of same for delivering a nucleic acid. In particular, provided is the use or a method of using a compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a combination comprising the compound of formula I, the stereoisomer thereof or the pharmaceutically acceptable salt thereof to deliver a nucleic acid to a cell or subject, (I)

IPC Classes  ?

• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

Provided is a preparation method for herbal medicine, comprising the following steps: mixing one or more lipid components and/or with any one or more of the following: nucleic acid, compounds, and macromolecules; and performing heat treatment on the obtained mixture. Also provided is a method for extracting medicinal soup from plants, comprising the following steps: using a solvent to prepare extract solution of a plant; performing differential centrifugation of the extract solution; and using an aqueous solution to re-suspend the precipitate to provide the medicinal soup.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07C 219/00 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
• C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
• C07C 233/00 - Carboxylic acid amides
• C07F 9/09 - Esters of phosphoric acids
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to extracting multiple types of compounds or synthetic compounds capable of promoting nucleic acid delivery from a traditional Chinese medicine, promoting the absorption of a nucleic acid such as sRNA and the entry thereof into a target cell by using the extracted compounds or multiple combinations, and promoting the entry of the nucleic acid into a target site in an object body having such a need. The traditional Chinese medicine is selected from traditional Chinese medicine decoction pieces derived from Rhodiola rosea, Herba Taraxaci, Herba andrographitis, and Flos Lonicerae. The nucleic acid is used for treating diseases, such as heart, spleen, kidney, stomach, lung and/or bowel diseases.

IPC Classes  ?

• C07C 219/00 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
• C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
• C07C 233/00 - Carboxylic acid amides
• C07F 9/09 - Esters of phosphoric acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Disclosed is a use of a transport protein inhibitor in the preparation of a drug for preventing or treating diseases accompanied by increased PD-1 expression. The drug can effectively decrease the expression of PD-1 in specific CD8+T cells and enhance the killing effect of specific CD8+T cells on tumor cells.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is the use of a NOK gene and an expression product thereof in construction of an animal model of chronic B lymphocytic leukemia.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

A method for detecting cell membrane holes using an atomic force microscope, comprising the steps of: providing cells; fixing the cells in place; and observing the cells by means of an atomic force microscope. The holes are present in the cell membrane or pass through the cell membrane. By means of the present method, the presence of holes in the cell membrane can be accurately observed, and the size and depth of the holes can be accurately determined.

IPC Classes  ?

• G01Q 60/24 - AFM [Atomic Force Microscopy] or apparatus therefor, e.g. AFM probes

Abstract

Provided are applications of a miR-200c-3p microRNA and/or an inhibitor thereof in the preparation of drugs for treating lung injuries, and an inhibitor for a modified miR-200c-3p microRNA.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/00 - Drugs for disorders of the urinary system
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present application relates to extracting, from a traditional Chinese medicine, a plurality of compounds capable of prompting nucleic acid delivery or synthetic compounds, and promoting nucleic acid such as sRNA to absorb and enter a target cell using the extracted compounds or a plurality of combinations and promoting the nucleic acid to enter required target sites in vivo of an object.

IPC Classes  ?

• C07C 219/00 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
• C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
• C07C 233/00 - Carboxylic acid amides
• C07F 9/09 - Esters of phosphoric acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

A group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia are described.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/76 - Albumins
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

A pharmaceutical composition containing bupivacaine comprises: bupivacaine or a pharmaceutically acceptable salt thereof serving as an active ingredient; and one or more pharmaceutically acceptable carrier materials. Particularly, the pharmaceutical composition of the invention is a bupivacaine nanoparticle.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 23/00 - Anaesthetics
• A61P 23/02 - Local anaesthetics
• A61K 9/51 - Nanocapsules

Abstract

The present invention discloses an application of clofoctol for manufacturing a pharmaceutical product for treating human neuroglioma. The clofoctol is a pharmaceutical product for treating an upper respiratory tract infection. The clofoctol exerts a significant and specific inhibition of a glioma stem cell activity relative to a human neuroglioma cell or a normal human astroglia, human embryonic kidney cell, and human neural stem cell. A glioma stem cell treated with the clofoctol exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma. The invention specifically found that a clofoctol for treating an upper respiratory tract infection can achieve targeted inhibition of the glioma stem cell, and can thus be used in preparing a pharmaceutical product for treating human neuroglioma.The invention provides a novel therapeutic pharmaceutical product for treating human neuroglioma.

IPC Classes  ?

• A61K 31/055 - Phenols the aromatic ring being substituted by halogen
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention discloses an application of a gambogic amide for preparing a pharmaceutical product for treating a neuroglioma. The gambogic amide is a TrkA agonist and nerve growth factor (NFG) analog, and significantly and specifically inhibits glioma stem cell activity relative to a human neuroglioma cell and a human astroglia. A glioma stem cell treated with gambogic amide exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma. Specifically, the invention found that a micromolecular gambogic amide can achieve targeted inhibition of the glioma stem cell, and can thus be used in preparing a pharmaceutical product for treating human neuroglioma. The invention provides a novel therapeutic pharmaceutical product for treating human neuroglioma.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is a papillomavirus chimeric protein, the skeleton thereof being a papillomavirus L1 protein or a mutant thereof, at least one HPV58 type L2 protein or mutant polypeptide thereof being embedded on the skeleton. The present papillomavirus chimeric protein can be used for preparing a vaccine for preventing papillomavirus infections and infection induced diseases.

IPC Classes  ?

• C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Provided is a papillomavirus chimeric protein, the skeleton thereof being a papillomavirus L1 protein or a mutant thereof, at least one human papillomavirus 33-type L2 protein or mutant polypeptide thereof being embedded on the skeleton. The present papillomavirus chimeric protein can be used for preparing a vaccine for preventing papillomavirus infections and infection induced diseases.

IPC Classes  ?

• C12N 15/37 - Papovaviridae, e.g. papillomaviruses, polyomavirus, SV40
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Provided is a cell line deposited under the number of CGMCC11091 and preparation method thereof. The method comprises: using a critical downstream gene of the BMP signal, the Id1 gene, as a target, then designing dual reporter gene elements to insert in an Id1 genome, so as to construct a recombination vector, and transcribing the same in a human embryonic stem cell line. A compound upregulating expression of Id1 and obtained by screening with the cell line has an application in preparing a pharmaceutical treating pulmonary arterial hypertension.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

A conjugate formed by a HSP90 inhibition peptide and cytotoxic agent via linker conjugation and usage thereof in preparing medicine for preventing and/or treating tumor. The conjugate has three anti-tumor effects including targeting delivery, chemistry treatment and tumor destruction, and can increase a drug capability of destroying the tumor. A reduction in relative dosage can obviously reduce the toxicity induced by accumulation of chemotherapy drugs.

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Provided are a small nucleic acid molecule, DNA molecule and protein for preventing and/or treating Ebola viral hemorrhagic fever and the use thereof. The small nucleic acid molecule is the inhibitor of microRNA and/or microRNA precursor which are differentially expressed by Ebola infected cells, and can up-regulate the expression of target genes of microRNA, thereby improving the resistance of cells to Ebola infection.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 31/14 - Antivirals for RNA viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed is a use of a ZFP28 variation point in the preparation of a schizophrenia diagnostic kit. An exome sequencing method is employed by the present invention to discover a new susceptibility gene ZFP28 of schizophrenia. The variation point of the ZFP28 gene is selected from c.1441T>C, c.961G>A, c.1052T>C, c.1081C>T, c.1511C>T, c.1170G>T, c.1208A>G and c.2017T>C, wherein the variation point c.1441T>C is in coseparation with schizophrenia. Also disclosed is the use of the ZFP28 gene in drug development, and the ZFP28 gene serves as a potential drug target.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A portable paper chip capable of visually detecting chlorine ion content in sweat is provided with a double-layer structure of paper (3) which can generate color or fluorescence changes according to the pH and anion exchange paper (2) which is arranged on the lower surface of the paper. The paper chip can be used to visually detect the chlorine ion content in sweat, thereby monitoring physiological status and diagnosing cystic fibrosis diseases.

IPC Classes  ?

• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• G01N 21/80 - Indicating pH value
• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators

Abstract

The present invention provides a humanized monoclonal antibody in an extracellular domain of an anti-human death receptor 5 (DR5), comprising a light chain variable region amino acid sequence which has at least 90% identity of an amino acid sequence shown by the SEQ ID NO:1, a heavy chain variable region amino acid sequence which has at least 90% identity of an amino acid sequence shown by the SEQ ID NO:2, and a constant region with a human antibody function IgG1. The present invention further provides a coding nucleotide sequence of the humanized monoclonal antibody, a recombination eukaryon expression vector, and a production method for the antibody, composition and use thereof. The humanized monoclonal antibody of the present invention has a specific apoptosis inducing activity on various tumor cells in vitro and vivo, may be used alone or used in combination with a natural ligand tumor necrosis factor related apoptosis inducing ligand of the DR5 or other drugs, and used for treatment of various tumors and diseases related to high expression of the DR5.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/13 - Immunoglobulins
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• C12N 5/28 - Cells resulting from interspecies fusion one of the fusion partners being a human cell
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a use of the inhibitor of CXCL-10 in manufacture of medicine for treating and/or preventing lung injury. Specifically, the present invention provides the use of the inhibitor of CXCL-10 in manufacture of medicine for treating and/or preventing lung injury of mammals including human. The lung injury is induced by influenza viral infection, bacterial infection, fungal infection, and/or septicemia. The inhibitor of CXCL-10 can reduce or knock out the expression of CXCL-10 in mammals. The inhibitor of CXCL-10 is selected from antibodies specific for CXCL-10, siRNA, or any other chemical or biological substance reducing and/or knocking out the expression of CXCL-10.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics

Abstract

The present invention discloses a method for detecting genus Plasmodium in a sample. Furthermore, the present invention provides a composition and a kit for the detection of genus Plasmodium in a sample.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

The present invention relates to the use of chloroquine for the treatment and chlorpromazine for the prevention of pulmonary infection and injury. In particularly, the present invention relates to the use of chloroquine, chlorpromazine, derivatives thereof, mixtures thereof, or medicinal compositions containing the same for the preparation of medications for treating and/or preventing pulmonary infection and/or injury in mammals, including humans, caused by influenza viruses.

IPC Classes  ?

• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 9/08 - Solutions
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Disclosed is the use of acetylacetic acid in preparing drugs for promoting the proliferation of skeletal-muscle cells, the skeletal-muscle cells being myoblasts, wherein the acetylacetic acid promotes the proliferation of the skeletal-muscle cells by activating the ERK pathway so as to up-regulate the expression of a cyclin, such as cyclin D1. Also disclosed is the use of acetylacetic acid in preparing drugs for treating injuries to skeletal muscle, and a drug composition for promoting the proliferation of skeletal-muscle cells, containing acetylacetic acid and Insulin-like Growth Factor 1.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Disclosed is a use of an IL-17 inhibitor in preparation of drugs for treating and/or preventing lung injury. Specifically, a use of an IL-17 inhibitor in preparation of drugs for treating and/or preventing lung injury in mammalians comprising human is disclosed. The lung injury is caused by influenza virus infection, bacterial infection and/or fungal infection, or septicemia. The IL-17 inhibitor can lower or knock out the expression of IL-17 in mammalians, and is selected from a specific anti-IL-17 antibody, siRNA or any other substance able to lower or knock out the expression of IL-17.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention provides a human serum or plasma protein complex and the separation spectrum thereof, and the uses thereof in inflammation and/or immune-related chronic disease screening and/or prognosis evaluation, and medicinal efficacy evaluation, as well as a detection method for the diagnosis and/or prognosis evaluation of human immune and/or inflammation-related chronic diseases using the protein complex spectrum.

IPC Classes  ?

• C07K 17/04 - Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 27/447 - Systems using electrophoresis

Abstract

The present invention provides tags of epigenetic modification for predicting differential potential of stem cells. In particular, the present invention provides a method for predicting differential potential of stem cells, and uses of the status of histones modification of totipotent genes and/or differentiation associated genes as tags of epigenetic modification for predicting differential potential of stem cells. Relationships between status of histones modification of specific genes and the stem cells' differential status and its differential potential have been established, thereby providing guidance information for using stem cells reasonably in clinical.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Provided are a sub-totipotent stem cell product and apparent hereditary modifying label thereof, a method for inducing the generation of the sub-totipotent stem cell product and identification for the apparent hereditary modifying label of the differentiated potential of stem cells. Also provided is a use of a histone modifying state of a sub-totipotent gene and/or differentiated related gene to predict the apparent hereditary modifying label of the differentiated potential of stem cells.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12R 1/91 - Cell lines

Abstract

A magnetic composite material is consisted of: a) 10 to 50 grams of a polymer per 100ml organic solvent, wherein said polymer is selected from the group consisting of polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, polycaprolactone, polyamide and poly hydroxybutyric acid; b) 10 grams of hydroxyapatite nanoparticles per 100 ml organic solvent; and c) 2.5 grams of γ-Fe2O3 nanoparticles per 100 ml organic solvent, wherein said organic solvent is selected from the group consisting of tetrahydrofuran (THF), dimethyformamide (DMF), dimethylacetamide (DMAc), chloroform and dioxane. The application of the magnetic composite material in the regeneration and repair of bone tissue, the method to prepare the magnetic composite material and the product made from said magnetic composite material are also described.

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• A61L 27/02 - Inorganic materials

Abstract

The present invention relates to the use of RNF13 protein and encoding gene thereof in the preparation of medicaments for preventing and/or treating mental cognitive disorders. The present invention further relates to the use of RNF13 gene knockout mice in screening medicaments for preventing and/or treating mental cognitive disorders.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides the use of carboxyamidotriazole or pharmaceutically acceptable salts, analogues or derivatives thereof in the preparation of the medicaments for preventing or treating interstitial pneumonia or pulmonary fibrosis. The interstitial pneumonia or pulmonary fibrosis includes lithicosis, sarcoid, allergic pneumonia, drug-induced pneumonia, radiation pneumonia, infection, fibrosing alveolitis related to collagen vascular diseases. The present invention also provides the drug kits comprising the carboxyamidotriazole compounds.

IPC Classes  ?

• A61K 31/4192 - 1,2,3-Triazoles
• A61P 11/00 - Drugs for disorders of the respiratory system